Molecular Docking in Drug Discovery: A Review on Anti-snake Venom Development

Adewunmi Rofiat Funmilola\textsuperscript{1*}, Gidado Abubakar\textsuperscript{1} and Zanna Hassan\textsuperscript{1}

\textsuperscript{1}Department of Biochemistry, University of Maiduguri, Borno State, Nigeria.

\textbf{Authors’ contributions}

This work was carried out in collaboration among all authors. Author ARF wrote the first draft of the manuscript and managed the literature searches. Authors GA and ZH encourage author ARF to investigate (enzymes in snake venom) and supervised the findings. All authors contribute, read and approved the final manuscript.

\textbf{Article Information}

DOI: 10.9734/IJBCRR/2020/v29i330179

\textbf{Article Information}

Received 10 February 2020
Accepted 15 April 2020
Published 05 May 2020

\textbf{ABSTRACT}

Snakebite is a frequent accident faced by rural community’s dwellers, and it has remained a neglected public health problem in many countries. Snake venom is a complex mixture of proteins, and they participate to envenomation through a diverse array of bioactivities, such as bleeding, inflammation, and pain, cytotoxic, cardiotoxic or neurotoxic effects. The only approved and accepted treatment for snakebite envenoming is the use of antivenoms produced by the purification of IgG immunoglobulins immunized against specific snake venom. However, various technological approaches are being pursued by different research groups, including the use of small-molecule inhibitors, antibody-based bio-therapeutics and peptide-based aptamer against enzymatic toxins and non-enzymatic toxins in snake venom. Modern bioinformatics tools have been recently developed to mine snake venoms, helping focus experimental research on the most potentially interesting toxins. Some computational techniques predict toxin molecular targets, and the binding mode to these targets. This review presents molecular docking studies of potential targeted key enzymes in snake venom.

*Corresponding author: E-mail: Adewunmi_rofiat@yahoo.com;
Keywords: Molecular docking; drug discovery; snake venom; bioinformatics; envenomation.

1. INTRODUCTION

Snakebite is a frequent accident faced by villagers, and has remained a neglected public health problem in many countries even though it is difficult to be precise about the actual number of cases [1]. In sub-Saharan Africa alone, snakebite is estimated to cause between 435,000 to 580,000 envenomation and 20,000 to 32,000 deaths every year [2]. Amputation and disability, tetanus, gangrene, cortical necrosis of the kidneys etc., are among the medical manifestations of snakebite envenomation [2]. The five families of poisonous snakes are Colubridae, Elapidae, Hydrophidae, Viperidae and Atherididae. Snake venom is a complex mixture of different enzymes, which are proteins [3]. These enzymes determine the toxicity of the snake venom as to whether it is haemotoxic or neurotoxic but the venoms cannot be classified as being exclusively haemotoxic or neurotoxic. Prompt administration of antivenom is the cornerstone of effective snakebite management, although supportive care is crucial too, including assisted ventilation in case of neurotoxic envenomation [4]. The path to drug discovery is a long, expensive, challenging and arduous tasks, hence, computer aided drug design and discovery (CADD) is a rapidly growing area that has seen many successes in the last few years [5]. Computational drug discovery can help in identifying potent drug molecules and targets via bioinformatics tools, such as molecular docking. They can also be used to evaluate the target structures for possible binding/active sites, generate active drug molecules, check for their dynamic and kinetic properties [6,7]. Docking is frequently used to predict the binding orientation of small molecule drug candidates to their protein targets in order to predict the affinity and activity of the small molecule. Hence docking plays an important role in the rational drug design [8].

2. MOLECULAR DOCKING

Molecular docking is the process that involves placing molecules in appropriate configurations to interact with a receptor [9]. Molecular docking is one of the most frequently used methods in structural based drug design (SBDD) because of its ability to predict, with a substantial degree of accuracy, the conformation of small-molecule ligands within the Molecules appropriate target binding site [10].

![Fig. 1. Outline of the molecular docking process. (A) Three-dimensional structure of the ligand; (B) Three-dimensional structure of the receptor; (C) The ligand is docked into the binding cavity of the receptor and the putative conformations are explored; (D) The most likely binding confirmation and the corresponding intermolecular interactions are identified [11](image)](image-url)
2.1 Molecular Docking Models

Over the years, biochemists have developed numerous models to capture the key elements of the molecular recognition process. The models are:

I. **The Lock and Key Theory**: As far back as 1890, Emil Fischer proposed a model called the “lock-and-key model, where a substrate fits into the active site of a macromolecule, just like a key fits into a lock. Biological ‘locks’ have unique stereo-chemical features that are necessary to their function [12].

II. **The Induced-Fit Theory**: In 1958, Daniel Koshland introduced the “induced-fit theory”. The basic idea is that in the recognition process, both ligand and target mutually adapt to each other through small conformational changes until an optimal fit is achieved [13].

2.2 Application of Molecular Docking in Drug Development

Drug discovery can be described as the process of identifying chemical entities that have the potential to become therapeutic agents [14]. The process of drug discovery is time consuming, tedious and expensive. Therefore, Molecular docking has become one of the most important modeling tools in modern drug discovery because it is a very convenient and cheap means to study protein-ligand interactions, which can be used to develop more potent, selective and efficient drug candidates [15]. The application of molecular docking in drug discovery process include the following:

i. **Hit identifications**: Docking in combination with scoring function can be used to evaluate large databases for finding out potent drug candidate, which can target the molecule of interest.

ii. **Side effect prediction**: Docking-based tools have predicted the efficacy of potential therapeutic compounds and have also helped in predicting the range of unintended and undesired interactions between the specific compound and the human proteome. It also plays a prominent role in the initial prediction of drug’s binding properties to nucleic acid. This information establishes the correlation between drug’s molecular structure and its cytoxicity.

iii. Molecular docking can be used to establish mechanisms of action a potent drug candidate against a molecular target.

3. **VENOM MOLECULAR TARGETS**

Numerous snake venom proteins have been identified as druggable or potentially druggable targets, including phospholipases A2 (PLA2s), metalloproteinases (SVMP), serine proteases (SVSP), kallikrein-like serine proteases, 5’nucleotidase, ATPase, alkaline phosphomonoesterase and acetylcholine esterase, and many of these have been characterized crystallographically. These protein crystal structures serve as structural models for in-silico screening using molecular docking techniques. Often, there are different structures, usually with different co-crystallized ligands, that can provide slightly different and complementary binding sites for docking studies [6].

4. **PHOSPHOLIPASE A2**

PLA2s are a group of esterolytic enzymes present in snake venoms that typically catalyze the breakdown of glycerophospholipids, the main component of biological membranes, into lysophospholipids and a fatty acid [16]. PLA2s are found in the venoms of Viperidae, Elapidae, and Colubridae snakes. The lengths of PLA2s vary from 119–134 amino acids, and they share a common scaffold of four main helices with seven intrachain disulfide bonds [17]. The snake venom PLA2s are split into two groups, group I PLA2s are found predominantly in elapid and some colubrid snakes, while group II are found only within Viperidae [18,15]. Group I are generally β-neurotoxins which act pre-synaptically, sometimes binding to voltage gated potassium channels [18]. After binding, neurotoxic PLA2s can sometimes hydrolyze nerve terminal phospholipids causing permanent neurotoxicity [16]. This has the effect of causing paralysis, while group II PLA2s tend to act cytotoxically, predominantly as myotoxins, causing myonecrosis via the disruption of the plasma membrane [17]. Indeed, both natural and synthetic PLA2 inhibitors are able to attenuate the morbidity and mortality of snake bite envenomation [19].

5. **COMPUTATIONAL STUDIES ON PHOSPHOLIPASE A2 INHIBITORS**

There are many reports on computational molecular modeling methods used for the development of PLA2 inhibitors that contribute to the attenuation of snake venom toxicity [20]. These applications use the x-ray crystallographic, 3D structural information
generated in the last few decades, and methods such as molecular dynamics (MD) simulations and docking. Structurally, snake venom PLA$_2$s is divided into classes I and II, this is based on their amino acid sequence and disulfide bonding pattern [21]. However, they have a conserved structure which contains an N-terminal α-helix (H1), a Ca$^{2+}$-binding loop, two antiparallel α-helices (H2 and H3), a two-stranded antiparallel sheet (β-wing), and a long C-terminal loop. In general, folding is stabilized by seven disulfide bonds (with different pattern in classes I and II).

Nargotra and his co-researcher [22] evaluated allibary of natural products and synthetic molecules through docking studies on $D.~russelli$ PLA$_2$ to identify possible inhibitors. Their study lead to in silico identification of several molecules as PLA$_2$ Inhibitors, with most of them belonging to phenolic and substituted benzyaldehydic compounds [20]. The same authors proposed the docking poses inside PLA$_2$ of $D.~russelli$ for synthetic phenolic compounds effective against snake venom. They found that phenolic compounds having hydroxyl and methoxyl groups in their benzene ring showed maximum inhibitory potency. The majority of molecular modeling applications in literature for studying PLA$_2$s are oriented to rational design of novel inhibitors for the treatment of different Viperidae snakebites. In another work, Zhang and his collaborators [23] docked structural elements of the persimmon tannin PT40 (a highly galloylated condensed tannin with an unusual flavonol terminal unit) inside Chinese cobra (Naja atra) PLA$_2$ binding site, to understand the inhibitory mechanism of this natural product. They found that the residues Trp18, Try27, Gly29, His47, and Tyr63 are involved in the interactions. Pereañez and his colleagues [24] studied the mode of action of morelloflavone with PLA$_2$ of $Crotalus~durissus$, using docking. Authors found that morelloflavone occupies part of the substrate binding cleft of $C.durissus$ PLA$_2$, forming hydrogen bonds with the residues Gly33, Asp49, Gly53, and Thr68 of the enzyme, and π–π stacking with the residue Tyr52. The same authors used docking to investigate the interactions between $C.~durissus$ PLA2 and bile acids, such as cholic acid and ursodeoxycholic acid. Authors found that bile acids interact with the binding active site of PLA$_2$ through different interactions, cholic acid showed hydrogen bonds with His48, whereas, ursodeoxycholic acid showed hydrogen bonds with Asp49 and Tyr28. Also, Chavan and Deobagkar [25] applied molecular docking simulation techniques to propose the putative interactions of LT10 peptide (small synthetic peptide derived from N-terminal of the lethal toxin neutralizing factor) with N. naja PLA$_2$. Molecular docking was performed to analyze the stability of the complex obtained by docking method. Villar and his collaborators [26] demonstrated that synthetic inhibitor derivatives from nitrostyrene that contain typical nitro groups at the ortho-, meta-, and para- positions on the aromatic ring were more efficient against the enzymatic, edematogenic, and myotoxic activities of PLA$_2$s from $B.~jararacussu$ venom. In a related research, Da-silva and co-researchers [27] performed molecular modeling studies between Asp49-PLA$_2$ from $C.~adamanteus$ venom and synthetic derivatives polyhydroxy phenolic compounds, they concluded that some conformations of these groups might positively influence enzymatic activity inhibition.

Finally, Mohanapriya and his colleagues [28] investigated phospholipase A$_2$ inhibitory activity of some medicinal plants against Naja. naja venom using auto Dock. They observed that the molecular docking analysis of plant compounds against PLA$_2$ molecule shows the effective binding site in the C-terminal end (Ile104, Ala101), α- helix 3 (Val 47, Phe 46) and α- helix 4 (Asp122, Pro121). Therefore, they concluded that Aerva lanata could be an effective treatment in treating snake bite.

6. METALLOPROTEINASES (SVMPs):

Snake Venom Metalloproteinases (SVMPs) are zinc-dependent proteinases ranging from 20 to 110 kDa in size and are categorized into P-I, P-II, and P-III classes according to their structural domains [29]. Studies have found that the SVMP is most abundant components in snake venom particularly viper species. Previous research has shown that SVMP induces hemorrhage by directly affecting the capillary blood vessels by clearing key bonds of the basement membrane components in a highly selective fashion, and thus affecting the interaction between the basement membrane and the endothelium [30]. Previous research as revealed that metalloproteinase is a mediator for edema, local tissue damage, inflammation, and hemorrhage [31].

7. COMPUTATIONAL STUDIES ON SVMPs INHIBITORS

Sathish kumar and co [32] provides in depth analysis on model the SVMP protein and also the
identification of potent lead compounds (BD17344, BD905, BD 904, BD 25279, BD16837, BD13364, BD5228, BD17338, BD7951, BD26458, BD20708, BD16010, BD4991, BD5001, and BD15993) against SVMP. They modeled the 3D structure of the SVMP using different software and the best model was selected based on the stereochemical properties. The best lead compounds for SVMP were screened using different databases viz. Binding, Maybridge, Hitfinder, and TOSLab databases. They identified fifteen potent hits through the Glide score and Glide energy. It was conclusively shown that all the compounds are quite stable in the active site of SVMP and thus, the isolated compounds might show promising activity against SVMP when compared to screening compounds.

Senkatachalaiah and his colleagues [33] reported the inhibitory effect of compound 5d, an apigenin based molecule against SVMPs both in silico and in vivo. The researchers found that the molecular docking of compound 5d and bothropasin demonstrated the direct interaction of hydroxyl group of compound with Glu146 present in hydrophobic pocket of active site and does not chelate Zn\(^{2+}\). Hence, it is concluded that compound 5d could be a potent agent in viper bite management.

Pithayaukul and his collaborators [34] studied the ethanolic extract from seed kernels of Thai mango (Anacardiaceae) and its major phenolic principle (pentagalloylglucopyranose) inhibitory effects on the caseinolytic and fibrinogenolytic activities of Malayan pit viper and Thai cobra venoms in in vitro tests. Molecular docking studies revealed that the binding orientations of the phenolic principles were in the binding pockets of snake venom metalloproteinases (SVMPs). The phenolic principles could form hydrogen bonds with the three histidine residues in the conserved zinc-binding motif and could chelate the Zn\(^{2+}\) atom of the SVMPs, which could potentially result in inhibition of the venom enzymatic activities and thereby inhibit tissue necrosis.

In another research, Lina and co-researchers [35] investigated the interactions between triterpenes (Ursolic acid, Oleanolic acid, Madecassic acid, β-boswellic acid, Betulin and Betulnic acid) and snake venom metalloproteinase using molecular docking simulation. The simulations revealed the atomic interactions that underlie binding between the triterpenic acids, most notably the electrostatic interaction between carboxylate groups of the compounds. The researcher's findings suggested that the occlusion of the S10 sub-site is essential for inhibition of proteolytic activity of metalloproteinases. They also found out that pentacyclic triterpenes having a carboxylate group at their C-17 position (betulinic, madecassic, oleanolic and ursolic acids) inhibit metalloproteinase proteolytic activity in experiment and exhibit favorable binding free energies and occlusion of the S10 subsite in simulation.

Conclusively, Muthusamy and his colleagues [36] analyzed the role of Zn\(^{2+}\) and Ca\(^{2+}\) ions in the protein metalloproteinase activity using a compound clerodane diterpenoid by molecular docking. They performed molecular dynamics simulations up to 50ns using Desmond to understand the role of ligand in the active site of SVMP protein by various combinations. It was discovered that in the absence of both Zn\(^{2+}\) and Ca\(^{2+}\) ions from the protein, molecular docking simulation were fluctuating, particularly absence of Zn\(^{2+}\) ion with the protein. Based on the results, they concluded that the Zn\(^{2+}\) and Ca\(^{2+}\) ions have a vital role in the active site of SVMP protein.

8. SERINE PROTEINASES (SVSPs)

SVSPs are found in venoms of the snake families Viperidae, Elapidae, and Colubridae [37]. Venom Serine Proteinases (SVSPs) belong to the S1 family of serine proteinases and display molecular masses ranging from 26 to 67 kDa with two distinct structural domains [38]. It catalyzes the cleavage of covalent peptide bonds in proteins and plays key roles in diverse biological processes ranging from digestion to the control and regulation of blood coagulation, the immune system and inflammation [39]. The anticoagulant SVSPs activate protein C via a thrombomodulin-independent mechanism. The most studied SVSP enzyme is from Agkistrodon contortrix venom, commercially referred to as Protac, which specifically converts protein C to activated protein C by hydrolyzing the Arg169-Leu170 bond, functioning independently of plasmatic factors [40].

Subhamay and Iman [41] studied molecular interaction between serine protease and Hesperetin (one of the major flavonoid glycosides naturally present in several citrus fruits such as lemons and oranges) to investigations the likelihood of inhibition. The researchers obtained the amino acid sequence of thrombin-like serine protease from sharpened
pit viper snake venom from the online database system of National Centre for Biotechnology Information. Employing AutoDock as molecular docking analysis software, they discovered the ideal ligand binding pose of hesperetin which is in close proximity to catalytic residues of snake venom serine protease, i.e., serine, histidine, and aspartic acid. Therefore, the generated in silico results by the researchers suggests that the novel structure hesperetin - flavanone might act as a potent inhibitor of thrombin-like snake venom proteases, and unlocks the possibilities for designing drugs of the inhibitors of snake venom serine proteases.

In a similar research, Roney and his colleagues [42] investigated the inhibitory activity of citrus bioflavonoid, hesperetin on two thrombin-like snake venom serine proteases isolated from *Crotalus simus*. They performed the computational molecular docking studies to assess the possibility of serine protease thrombin-like being inhibited by flavonoids. Considering seven possible binding sites, their results suggest that hesperetin could form a hydrogen bond with Arg60 and His57 with the hydroxyl group on the carbon-5 from its A ring and oxygen atom 1 in the ring C could form hydrogen bonds with the Gly193 and Lys192. In addition, the methoxy group of the B ring could form hydrogen bond with the Gly216 and Asp217. They concluded that flavonome is an interesting inhibitor for snake venom serine proteases, and could open up a possibility for drug design of snake venom serine protease inhibitors.

9. CONCLUSION

Snake venoms are amongst the most fascinating animal venoms regarding their complexity and evolution. The generation and visualization of venom enzyme-inhibitor binding data from molecular docking simulation provide opportunity to explain structural features of enzyme inhibition mechanism. In this regard, molecular docking could be used as a pre-screen to identify compounds that are more likely to have different activity against a potential venom molecular target, which could lead to effective treatment of snake bite envenomation.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Reid HA. Snake bite, Tropical Doctor Z. 1972:155.
2. Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebitevenomung. Nature Reviews Disease Primer. 2017;3:17063.
3. Theakston RDG, Reid HA. Development of simple standard assay procedures for the characterization of snake venoms, Bulletin of the World Health Organization. 1983; 61:949–956.
4. Opadiojo OG, Omotosho AB. Snake bite in Ilorin: A review of 155 cases, Nigeria Medical Practitioner. 1996;32:30-32.
5. Gutiérrez JM, León G, Lomonte B, Angulo Y. Antivenoms for snakebite envenomings. Inflamm. Allergy Drug Targets. 2011;10: 369–380.
6. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: Methods and applications, Nature Review Drug Discovery. 2004;3(11):935–949.
7. Chaudhary KK, Mishra N. A review on molecular docking: Novel tool for drug discovery. Databases. 2016;3(4).
8. Gore M, Desai NS. Computer-aided drug designing, Methods Mol Biol. 1983;1168:313–321.
9. Ballante F. Protein-Ligand Docking in Drug Design: Performance Assessment and Binding-Pose Selection, Methods in Molecular Biology. 2018;1824:67–88.
10. Ballante F, Marshall GR. An Automated Strategy for Binding-Pose Selection and Docking Assessment in Structure-Based Drug Design. Journal of Chemical Information and Modeling. 2016;56(1):54–72.
11. Lomonte B, Calvete JJ. Strategies in ‘snake venomics’ aiming at an integrative view of compositional, functional, and immunological characteristics of venoms. J. Venom. Anim. Toxins Trop. Dis. 2017; 23.
12. Monika G, Punam G, Sarbjet S. An overview on molecular docking. International Journal of Drug Development & Research. 2010;2(2):229-231.
13. Avinash R, Veerabhada A, Rao A. A review on molecular docking, Novel tool in drug design and analysis. Journal of Harmonized Research in Pharmacy. 2013;2(4):215-218.
14. Drews J. Drug discovery: A historical perspective. Science. 2000;287:19601963.
15. Giersiepen H, Hilgenfeld R, Hillisch A. Modern Methods of Drug Discovery. Institute of Molecular Biotechnology, Beutenbergster. Germany. 2003;1:109-155.
16. Harrison RA, Hargreaves A, Wagstaff SC, Faragher B, Laloo DG. Snake Envenoming: A Disease of Poverty. PLoS Negl. Trop. Dis. 2009;3:56.
17. Dubovskii PV, Utkin YN. Cobra Cytotoxins: Structural organization and antibacterial activity. Acta Naturae. 2014;6:11-18.
18. Kini RM. Excitamentahead: Structure, function and mechanism of snake venom phospholipase A2 enzymes. Toxicon. 2003;42:827-840.
19. Boldrini-França J, Cologna CT, Pucca MB, Bordon KDCF, Amorim FG, Anjolette FAP, Cordeiro FA, Wiezal GA, Cerni FA, Pinheiro-Junior EL. Minor snake venom proteins: Structure, function and potential applications. Biochim. Biophys. ActaBBA-Gen. Subj. 2017;1861:824-838.
20. Manoj G. Tyagi“Development of Novel Phospholipasea2 Inhibitors Using Molecular and Computational Techniques. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS). 2018;13(2):05-12.
21. Qiu F, Chen Y, Liu L. Discovery of Novel Secretory Phospholipase A2 Inhibitors Using Virtual Screen. Chem. Biol. Drug. Des. 2014;84:216-222.
22. Nargotra A, Sharma S, Alam MI, Ahmed Z, Bhagat A, Tanjania SC, Qazi GN, Koul S. In Silicoidentification of Viper Phospholipasea2 Inhibitors: Validation By In Vitro, In Vivo Studies, J. Mol. 2011; 17:3063–3073.
23. Zhang Y, Zhong L, Zhou B, Chen JY, Li CM. Interaction of characteristic structural elements of persimmon tannin with Chinese cobra pla2. Toxicon. 2013;74:34–43.
24. Pereanez JA, Patino AC, Nunez V, Osorio E. The b flavonoid morfellosfone inhibits the enzymatic and biological activities of a snake venom phospholipase a2. Chem. Biol. Interact. 2014;220:94–101.
25. Chavan SG, Deobagkar DD. In silico molecular interaction analysis of LTNP peptide-LT10 with snake venom enzymes, Protein Pept. Lett. 2014;21:646–656.
26. Villar FPF, Lima TD, Veber CL. Synthesis and evaluation of nitrostyrene derivative compounds, new snake venom phospholipase A2 inhibitors. Toxicon. 2008;51(8):1467–1478.
27. Da Silva SL, Calgarotto AK, Maso V. Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds. European Journal of Medicinal Chemistry. 2009;44(1):312–321.
28. Mohanpriya M, Nandhini AR, Praveen KP, Yogamandhini G, Gowri-Shankar BA. Anti-phospholipase activity of medicinal plants against Naja naja venom, Int. Res. J. Pharm. 2017; 8(10):189-195.
29. Gutiérrez JM, Theakston RDG, Warrell DA. Confronting the neglected problem of snake bite envenoming: The need for a global partnership. PLoS Med. 2016;3:150.
30. Laustsen AH, Johansen KH, Engmark M, Andersen MR. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease PLoS Negl. Trop. Dis. 2017;11:5361.
31. Markland FS, Swenson S. Snake venom metalloproteinases. Toxicon. 2013;62:3–1.
32. Sathishkumar C, Selvakumar C, Selvaraman N, Karthikeyan M. Identification of potent inhibitors against snake venom metalloproteinase (SVMP) using molecular docking and molecular dynamics studies, Journal of Biomolecular Structure and Dynamics. 2014;33(7):1-33.
33. Venkatalakshmi S, Mahalingam SS, Sebastian A, Mahadevappa H, Siddaiah C, Nayaka K, Kempoju B, Kesturu S, Girish, Kanchugarakoppal SR. Novel Apigenin Based Small Molecule that Targets Snake Venom Metalloproteinases, Toxin. 2019;19:22.
34. Pithayanukul P, Leanoiphareanchai J, Saparpakorn P. Molecular docking studies and anti-snake venom metalloproteinase activity of Thai mango seed kernel extract; 2009.
35. Lina MP, Jaime AP, Ettayaparam RS, Jeffrey C. Interactions between Triterpenes and a P-I Type Snake Venom Metalloproteinase: Molecular Simulations and Experiments, TOXIN. 2018;8.
36. Muthuvasy K, Sathishkumar C, Subbiah N, Thirunavukkarasu S. Computational and in vitro insightson snake venom phospholipase A2 inhibitor of phytochemical ikshusterol 3-O-glucoside of Clematis gourians, Journal of Biomolecular Structure and Dynamics. 2017,36(16): 4197-4208.
37. Serrano SM. The long road of research on snake venom serine proteinases, Toxicon. 2013; 62:19-26.

38. Fernández J, Alape-Girón A, Angulo Y, Sanz L, Gutiérrez JM, Calvete JJ, Lomonte B. Venomic and antivenomic analyses of the Central American coral snake, Micrurus nigrocinctus (Elapidae). J. Proteome Res. 2011;10:1816–1827.

39. Matsui T, Fujimura Y, Titani K. Snake venom proteases affecting hemostasis and thrombosis, Biochim Biophys Acta. 2000;1477:146-56.

40. Panfoli I, Calzia D, Ravera S, Morelli A. Inhibition of hemorrhagic snake venom components: Old and new approaches. Toxins (Basel). 2010;2:417-27.

41. Subhamay P, Iman E. Molecular docking studies of snake venom serine protease of sharp-nosed pit viper with hesperetin Article in Asian Journal of Pharmaceutical and Clinical Research. 2018;11(6):457-461.

42. Roney V, Villalta-Romero F, Stanisic D, Borro L, Neshich G, Tasic L. Citrus bioflavonoids, hesperetin, as inhibitor of two thrombin-like snake venom serine proteases isolated from Crotalus simus, Toxicon. 2018;143:36-43.